Document is current

Article History

Received: 5 March 2024

Accepted: 30 July 2024

First Online: 5 August 2024

Competing interests

: FTJ, SY, IN and CKC have no conflicts of interests to report. BAC reports personal fees from Pfizer, outside of the submitted work. TPD reports personal fees from Teva, outside of the submitted work. DB reports presentations (TEVA, Novartis, Pfizer), travel support (Allergan, TEVA, Pfizer, Abbvie), advisory boards (Novartis, Lilly, Teva, Lundbeck, Pfizer, Abbvie) and participations in clinical trials (TEVA, Lundbeck, Novartis, Lilly, Novo Nordic Foundation) outside the submitted work and received grants from Odense University Hospital and Rigshospitalet, University of Copenhagen and the Region of Southern Denmark not related to this work. FMA has received Honoria or personal fees from Pfizer, Teva, Novartis, Lundbeck, AbbVie and Eli Lilly for lecturing or participating in advisory boards; is principal investigator for phase IV trials sponsored by Novartis and by Teva; serves as president of Danish Headache Society and board member of the European Headache Federation; serves as associate editor for Acta Neurol Scand, Front Neurol, Front Res Pain, and Headache Medicine; serves as junior associate editor for Cephalalgia and Cephalalgia Reports; member of the editorial board of J Headache Pain.